Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Price Target at $52.33

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $52.3333.

KNSA has been the topic of a number of analyst reports. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $45.37 on Thursday. The stock has a fifty day moving average of $42.21 and a 200-day moving average of $38.91. The company has a market capitalization of $3.44 billion, a P/E ratio of 100.82 and a beta of 0.06. Kiniksa Pharmaceuticals International has a fifty-two week low of $18.25 and a fifty-two week high of $46.65.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 17,845 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at $523,082.08. This trade represents a 59.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barry D. Quart sold 2,690 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $45.00, for a total transaction of $121,050.00. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $564,570. This trade represents a 17.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 136,293 shares of company stock worth $5,759,230 over the last ninety days. Corporate insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently modified their holdings of KNSA. Amundi acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after acquiring an additional 1,002 shares during the last quarter. Millennium Management LLC raised its stake in Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Nordea Investment Management AB raised its stake in Kiniksa Pharmaceuticals International by 1.6% during the second quarter. Nordea Investment Management AB now owns 130,160 shares of the company’s stock worth $3,582,000 after acquiring an additional 2,110 shares in the last quarter. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $479,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.